Checkpoint Trends Ltd Hits New 52-Week High at Rs.125.9

2 hours ago
share
Share Via
Checkpoint Trends Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 2 Jan 2026 by hitting a new 52-week and all-time high of Rs.125.9, marking a notable surge in its stock price and reflecting strong momentum in recent trading sessions.



Strong Rally and Price Momentum


The stock of Checkpoint Trends Ltd demonstrated robust performance, opening the day with a gap up of 4.96% and maintaining this level throughout the trading session. The intraday high matched the opening price at Rs.125.9, underscoring sustained buying interest and price stability at this elevated level. This marks a remarkable increase from its 52-week low of Rs.9.41, highlighting an extraordinary appreciation of over 1,200% within the past year.


Checkpoint Trends Ltd has been on a consistent upward trajectory, registering gains for five consecutive trading days. Over this period, the stock delivered a cumulative return of 27.55%, significantly outperforming its sector peers. On the day of the new high, it outperformed the Pharmaceuticals & Biotechnology sector by 4.99%, signalling strong relative strength within its industry group.



Technical Indicators Confirm Uptrend


Technical analysis further supports the bullish momentum, with the stock trading above all key moving averages — including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This alignment of short-, medium-, and long-term averages indicates a sustained uptrend and positive investor sentiment. Such technical positioning often reflects healthy demand and can act as a foundation for continued price strength.



Market Context and Comparative Performance


The broader market environment also provided a supportive backdrop for Checkpoint Trends Ltd’s rally. On the same day, the Sensex opened flat but gained 0.31% to trade at 85,452.05 points, inching closer to its own 52-week high of 86,159.02, just 0.83% away. The Sensex’s positive momentum was led by mega-cap stocks, with the index trading above its 50-day moving average, which itself is positioned above the 200-day moving average — a classic bullish configuration.


Despite the Sensex’s modest gains, Checkpoint Trends Ltd’s one-year performance stands out dramatically. The stock has surged by 903.99% over the past 12 months, dwarfing the Sensex’s 6.94% rise during the same period. This exceptional outperformance highlights the company’s unique growth trajectory within the Pharmaceuticals & Biotechnology sector.




Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.



  • - Strong fundamental track record

  • - Consistent growth trajectory

  • - Reliable price strength


Count on This Pick →




Mojo Score and Rating Upgrade


Checkpoint Trends Ltd currently holds a Mojo Score of 54.0, reflecting a moderate strength in its overall market and fundamental metrics. Notably, the company’s Mojo Grade was upgraded from Sell to Hold on 4 Sep 2025, signalling an improvement in its underlying business and market positioning. The Market Cap Grade stands at 4, indicating a mid-tier market capitalisation relative to its peers.


The stock’s recent price action and rating upgrade suggest a positive reassessment of its prospects by market analysts, aligning with the strong price momentum observed in recent weeks.



Sector and Industry Positioning


Operating within the Pharmaceuticals & Biotechnology sector, Checkpoint Trends Ltd benefits from the sector’s ongoing innovation and demand for healthcare solutions. The sector has shown resilience and selective strength in the current market cycle, with Checkpoint Trends Ltd emerging as a notable outperformer. Its ability to sustain gains above key technical levels and outperform sector benchmarks underscores its competitive positioning.



Trading Activity and Price Stability


On 2 Jan 2026, the stock opened at Rs.125.9 and traded steadily at this price throughout the session, indicating a lack of significant selling pressure at the new high. This price stability at elevated levels is often a positive sign, suggesting that the market is absorbing the gains and consolidating before any further moves. The day’s 4.96% gain also reflects strong demand and confidence among market participants.




Considering Checkpoint Trends Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!



  • - Better options discovered

  • - Pharmaceuticals & Biotechnology + beyond scope

  • - Top-rated alternatives ready


Compare & Switch Now →




Summary of Key Metrics


To summarise, Checkpoint Trends Ltd’s stock performance as of 2 Jan 2026 is characterised by:



  • New 52-week and all-time high price of Rs.125.9

  • Five consecutive days of gains, with a 27.55% return over this period

  • Outperformance of the Pharmaceuticals & Biotechnology sector by 4.99% on the day

  • Trading above all major moving averages (5, 20, 50, 100, 200-day)

  • Mojo Score of 54.0 and upgraded Mojo Grade from Sell to Hold

  • Market Cap Grade of 4, indicating mid-tier capitalisation

  • One-year return of 903.99%, vastly exceeding the Sensex’s 6.94% gain



These metrics collectively illustrate a stock that has demonstrated exceptional price appreciation and technical strength over the past year, culminating in the recent milestone of a new 52-week high.



Market Environment and Broader Implications


The broader market’s positive tone, with the Sensex trading near its own 52-week high and supported by mega-cap leadership, provides a conducive environment for stocks like Checkpoint Trends Ltd to sustain their momentum. The alignment of sectoral strength and favourable technical indicators reinforces the significance of the company’s recent price achievement.



Conclusion


Checkpoint Trends Ltd’s attainment of a new 52-week high at Rs.125.9 marks a significant milestone in its market journey. Supported by strong technical indicators, a substantial rally over recent days, and an impressive one-year performance, the stock’s price action reflects a period of sustained strength within the Pharmaceuticals & Biotechnology sector. The upgrade in its Mojo Grade and solid fundamental scores further underscore the company’s improved market standing as of early 2026.






{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News